Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies-Reference-Cited by-同舟云学术

Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies

Published:2021-03-03 Issue:7 Volume:56 Page:1691-1699
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Shimomura Yoshimitsu^ORCID,Hara Masahiko,Yamamoto Hisashi,Uchida Naoyuki^ORCID,Kawakita Toshiro,Ashida Takashi,Takada Satoru,Ikeda Takashi^ORCID,Morishige Satoshi,Maruyama Yumiko^ORCID,Wake Atsushi,Ichinohe Tatsuo^ORCID,Fukuda Takahiro,Takanashi Minoko,Atsuta Yoshiko^ORCID,Ishikawa Takayuki

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-021-01217-w.pdf

Reference38 articles.

1. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol J Am Soc Clin Oncol. 2010;28:3730–8.

2. Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault De Latour R. et al. Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Ann Oncol J Eur Soc Med Oncol. 2017;28:2191–8.

3. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2002;8:468–76.

4. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857–64.

5. Ben-Barouch S, Cohen O, Vidal L, Avivi I, Ram R. Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis. Bone Marrow Transpl. 2016;51:232–40.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study;Bone Marrow Transplantation;2024-02-08

2. Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies;Frontiers in Oncology;2022-11-25

3. Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation;Pediatric Blood & Cancer;2022-11-17

4. Favorable Outcome with Conditioning Regimen of Flu/Bu4/Mel in Acute Myeloid Leukemia Patients in Remission Undergoing Cord Blood Transplantation;Transplantation and Cellular Therapy;2022-11

5. Intensified conditioning regimens improved disease‐free survival and engraftment after unrelated single‐unit cord blood transplantation but not after matched sibling or matched unrelated donor allogeneic hematopoietic cell transplantation;Hematological Oncology;2022-10-31